B Hossein Rashidi1, S Shams1, M Shariat2, H Kazemi Jaliseh1, M Mohebi1, F Haghollahi3. 1. Vali-e-Asr Reproductive Health Research Center, Tehran University of Medical Sciences, Tehran, Iran. 2. Maternal, Fetal and Neonatal Research Center, Tehran University of Medical Sciences, Tehran, Iran. 3. Vali-e-Asr Reproductive Health Research Center, Tehran University of Medical Sciences, Tehran, Iran. fedyeh_hagh@yahoo.com.
Abstract
PURPOSE: Polycystic ovary syndrome (PCOS) is the most common cause of chronic anovulation with a prevalence of 5-10% in women of reproductive age. The etiology of this disease is not well known, and hepcidin is one of the factors affecting the pathogenesis of the disease. The aim of this study was to evaluate plasma levels of hepcidin in patients with PCOS and its correlation with serum iron level. METHODS: In this case-control study, plasma levels of hepcidin, IL-6, and ferritin using ELISA method and serum iron levels using a spectrophotometric method were tested on 56 women with PCOS (case group) and 41 healthy subjects (control group). The results were analyzed using t test, General Linear Model, Binary logistic regression, and linear regression tests. RESULTS: The mean hepcidin levels were 1.97 ± 0.53 and 2.40 ± 0.25 pg/ml in the case and control groups, respectively. The t-test results showed significant difference between the two groups (p = 0.0001). The mean serum iron levels were 72.89 ± 28.97 and 70.62 ± 31.18 g/dl in the case and control groups, respectively. The t test analysis indicated no significant difference between the two groups. The serum ferritin and iron levels had no significant relation with serum hepcidin level in two groups. CONCLUSION: Despite the differences in the serum levels of hepcidin between the two groups, no significant relation was observed between serum iron levels and hepcidin level in this group of patients. This implies the need for more comprehensive studies on gene expression in hepcidin and iron pathways using real-time and Western techniques to investigate more precisely serum hepcidin level and its relationship with the factors mentioned.
PURPOSE:Polycystic ovary syndrome (PCOS) is the most common cause of chronic anovulation with a prevalence of 5-10% in women of reproductive age. The etiology of this disease is not well known, and hepcidin is one of the factors affecting the pathogenesis of the disease. The aim of this study was to evaluate plasma levels of hepcidin in patients with PCOS and its correlation with serum iron level. METHODS: In this case-control study, plasma levels of hepcidin, IL-6, and ferritin using ELISA method and serum iron levels using a spectrophotometric method were tested on 56 women with PCOS (case group) and 41 healthy subjects (control group). The results were analyzed using t test, General Linear Model, Binary logistic regression, and linear regression tests. RESULTS: The mean hepcidin levels were 1.97 ± 0.53 and 2.40 ± 0.25 pg/ml in the case and control groups, respectively. The t-test results showed significant difference between the two groups (p = 0.0001). The mean serum iron levels were 72.89 ± 28.97 and 70.62 ± 31.18 g/dl in the case and control groups, respectively. The t test analysis indicated no significant difference between the two groups. The serum ferritin and iron levels had no significant relation with serum hepcidin level in two groups. CONCLUSION: Despite the differences in the serum levels of hepcidin between the two groups, no significant relation was observed between serum iron levels and hepcidin level in this group of patients. This implies the need for more comprehensive studies on gene expression in hepcidin and iron pathways using real-time and Western techniques to investigate more precisely serum hepcidin level and its relationship with the factors mentioned.
Entities:
Keywords:
Hepcidin; Poly Cystic ovary Syndrome; Serum Ferritin; Serum Iron
Authors: Alberto Piperno; Stefania Galimberti; Raffaella Mariani; Sara Pelucchi; Giulia Ravasi; Carolina Lombardi; Grzegorz Bilo; Miriam Revera; Andrea Giuliano; Andrea Faini; Veronica Mainini; Mark Westerman; Tomas Ganz; Maria Grazia Valsecchi; Giuseppe Mancia; Gianfranco Parati Journal: Blood Date: 2010-12-13 Impact factor: 22.113
Authors: Manuel Luque-Ramírez; Francisco Alvarez-Blasco; José I Botella-Carretero; Raul Sanchón; José L San Millán; Héctor F Escobar-Morreale Journal: Diabetes Care Date: 2007-05-29 Impact factor: 19.112
Authors: José Manuel Fernández-Real; Francesco Equitani; José María Moreno; Melania Manco; Francisco Ortega; Wifredo Ricart Journal: J Clin Endocrinol Metab Date: 2008-12-30 Impact factor: 5.958
Authors: Nadiah A ALhabardi; Osama Al-Wutayd; Khalid M Eltayieb; Yasir S Shiha; Ahmad I Al-Shafei; Ishag Adam Journal: J Int Med Res Date: 2020-09 Impact factor: 1.671
Authors: Enrico Carmina; Brigitte Dreno; W Anne Lucky; W George Agak; Anuja Dokras; Jin Ju Kim; Rogerio A Lobo; Fahimeh Ramezani Tehrani; Daniel Dumesic Journal: J Endocr Soc Date: 2022-02-06